Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin

Sponsor
Assistance Publique - Hôpitaux de Paris
Study ID
NCT05977803
Status
Recruiting
Apply to this trial

Conditions

  • Brain Metastases
  • Pulmonary Cancer
  • Radionecrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MRI with CEST sequence, IVIM and ASL sequence — RADIATION
    Three sequences will be added as part of the protocol (for an additional duration of about 10 minutes) : * The CEST sequence * The ASL infusion sequence * The IVIM sequence

Study Details

The aim of the study is to determine whether the use of the CEST sequence would have diagnostic performance equivalent to the reference method of T2\* infusion with contrast injection in the diagnosis of radionecrosis of lung cancer brain metastases.

Key Dates

First listed
Aug 4, 2023
Start date
Feb 15, 2024
Status verified
Mar 2026
Primary completion
Feb 15, 2029
Completion
Mar 15, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: Radiation therapy
    Patient treated for metastatic cerebral lung cancer who has been treated with external beam radiotherapy such as in toto brain irradiation or stereotactic radiosurgery followed in the thoracic oncology department of Bichat Hospital.

Primary Outcome Measure

Visually significant hyperperfusion on normalized cerebral blood flow mapping generated from T2* infusion data with injection, confirmed by quantitative measurement of a ratio > 2.5 between tumor DSC and contralateral white matter. [ Time Frame: 24 months ]

Central Contacts

Related Studies